Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer

Shi, Liangrong; Wu, Changping; Wu, Jun; Zhou, Wenjie; Ji, Mei; Zhang, Hongyu; Zhao, Jiemin; Huang, Yuanquan; Pei, Honglei; Li, Zhong; Ju, Jingfang; Jiang, Jingting

doi:10.1186/1748-717x-7-114

Cited by 13 publications

(8 citation statements)

References 33 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…125 I seed implantation is a minimally invasive, widely used treatment that has unique advantages in the treatment of locally advanced tumors ( 11 , 12 ). In the US, radioactive seed implantation has been used as the standard treatment for early prostate cancer ( 13 ).…”

Section: Discussionmentioning

confidence: 99%

Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review

Feng¹,

Hu²,

Jin³

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Recurrent cervical cancer is a clinically complex disease that is difficult to treat. There are numerous treatment options, but the results achieved by each are poor. External-beam radiation therapy of the pelvic lymph drainage area, in combination with intracavitary afterloading or the interstitial implantation of a radiation source (i.e., brachytherapy), are the current standard radiotherapy regimens used in high-risk clinical targets. However, there are few reports concerning the use of iodine-125 (125I) seed implantation brachytherapy in recurrent cervical cancer, and the effects of treatment and adverse reactions have not yet been systematically evaluated. In the present study one such case is reported, in which the patient was successfully treated with intensity-modulated radiotherapy (IMRT) in combination with 125I seed implantation. The patient, a 47-year-old woman, was initially diagnosed with International Federation of Gynecology and Obstetrics stage IB1 cervical cancer, and received a radical hysterectomy, left lateral adnexectomy and pelvic lymph node dissection. A follow-up examination 23 months later revealed vaginal invasion and a solitary lump in the cervical stump with a maximum diameter of 38 mm. The patient was subsequently diagnosed with recurrent cervical cancer and was treated with six cycles of docetaxel and nedaplatin chemotherapy, alongside IMRT and interstitial 125I seed implantation. At the point of manuscript submission, the patient's progression-free survival time was 33 months and long-term adverse reactions were acceptable. The response of this patient indicates that 125I seed implantation could be used as a complementary treatment for recurrent cervical cancer and may also prove to be a reliable means for the comprehensive treatment of primary cervical cancer, as the patient had characteristics similar to primary cervical cancer, although this hypothesis could not be confirmed in the present study.

show abstract

Section: Discussionmentioning

confidence: 99%

Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review

Feng¹,

Hu²,

Jin³

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…The efficacy of brachytherapy in recurrent gastric cancer was demonstrated in a recent case series. Complete tumor response rate of 50% and partial response rate of 28.6% were achieved respectively . However, our experience with brachytherapy for gastric conduit cancer is limited.…”

Section: Discussionmentioning

confidence: 92%

Post-esophagectomy gastric conduit cancers: treatment experiences and literature review

Tong

Tsang

et al. 2013

Dis Esophagus

View full text Add to dashboard Cite

Esophagectomy remains the mainstay of treatment for esophageal cancer. The stomach is the commonest organ used to restore intestinal continuity after esophagectomy. Metachronous gastric cancer in the gastric conduit after esophagectomy is rare; the etiology remains unclear. Possible risk factors include Helicobacter pylori infection, biliary or pancreatic reflux and prior radiotherapy. Prognosis of these patients remains poor. Treatment of this particular entity poses unique challenges to the surgeon and oncologist. Early diagnosis by endoscopy may allow endoscopic excision such as endoscopic mucosal resection or endoscopic submucosal dissection. In more advanced cancers, surgery is difficult, reconstruction is complicated, and further radiation may not be feasible because of previous neoadjuvant therapy. In this report, four patients who developed gastric conduit cancers are presented. They were treated with either surgery alone or combined with chemoradiotherapy. All four patients were still alive after at least 21 months, with three patients currently still alive (21-48 months). The literature is also reviewed, in particular addressing the incidence, possible underlying causes, prognosis and options of treatment for this specific clinical scenario.

show abstract

“…To get a more comprehensive and reliable evaluation of effectiveness between RTDPTB and CCTB, several studies based on CCTB reported in the literature were also analyzed [ 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ]. The relevant information was summarized in Table 6 .…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of a robot-assisted 3D personalized template in 125I seed brachytherapy of thoracoabdominal tumors

Ma¹,

Yang²,

Jiang³

et al. 2018

jcb

View full text Add to dashboard Cite

PurposeThis research aims to evaluate the effectiveness and safety of a robot-assisted 3D personalized template in 125I seed brachytherapy of thoracoabdominal tumors.Material and methodsForty-three patients with different tumors were involved in this research between 2013 and 2015. They were all eligible to 125I seed implantation based on robot-assisted 3D personalized template. Meanwhile, 51 patients with similar tumors, which were treated with a conventional coplanar template, were involved for comparison. Follow-up was carried out after the surgery to evaluate the therapeutic efficacy, including overall survival (OS) of the patient and local control (LC) of the tumor. Complications were also summarized to evaluate the safety. Besides, statistical analysis was achieved to investigate possible factors associated with the result.ResultsIn the robot-assisted 3D personalized template-guided brachytherapy, the median target volume treated by the prescription dose (V100) was 95.3% (range, 92.4-109.8), and the median dose administered to 90% of the target volume (D90) was 126.1 Gy (range, 114.2-132.0), improved 5% and 8% compared with the conventional template-guided brachytherapy, respectively. The median OS was 30 months (95% CI: 19.4-40.6) and the rates of 2-year OS and LC were 58.1% and 86.0%, respectively. The median OS was prolonged 10 months and the 2-year OS and LC were improved 18.9% and 23.3% compared with the conventional template-guided brachytherapy, respectively.ConclusionsThrough analysis of the selected patients with thoracoabdominal tumors, the robot-assisted 3D personalized template in 125I seed brachytherapy was a more effective and safer method. It can achieve a more favorable OS and LC.

show abstract

Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer

Cited by 13 publications

References 33 publications

Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review

Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review

Post-esophagectomy gastric conduit cancers: treatment experiences and literature review

Effectiveness and safety of a robot-assisted 3D personalized template in 125I seed brachytherapy of thoracoabdominal tumors

Contact Info

Product

Resources

About